Acute promyelocytic leukemia after iodine-131 therapy for Graves' disease

Pharmacotherapy

Volumn 25, Issue 7, 2005, Pages 1017-1020

  Kolade, Victor O ^a   Bosinski, Timothy J ^b   Ruffy, Enrico L ^c  

^a ERIE COUNTY MEDICAL CENTER   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c KINGSBROOK JEWISH MEDICAL CENTER   (United States)

Author keywords

Acute promyelocytic leukemia; Graves' disease; Radioiodine

Indexed keywords

IDARUBICIN; IODINE 131; LEVOTHYROXINE; MITOXANTRONE; PROPRANOLOL; PROPYLTHIOURACIL; RETINOIC ACID; THYROXINE;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; FEMALE; FOLLOW UP; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IONIZING RADIATION; LEUKEMIA REMISSION; PATIENT MONITORING; PHYSICAL EXAMINATION; PROMYELOCYTIC LEUKEMIA; RADIATION DOSE; RADIOISOTOPE THERAPY; THYROID FOLLICLE CELL; THYROID FUNCTION; THYROID SCINTISCANNING; THYROXINE BLOOD LEVEL; TOXIC GOITER;

FEMALE; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; LEUKEMIA, PROMYELOCYTIC, ACUTE; MIDDLE AGED; RADIOPHARMACEUTICALS;

EID: 21444454236     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.7.1017     Document Type: Article

References (31)

1. Torring O, Tallstedt L, Wallin G, et al. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine: a prospective, randomized study. Thyroid study group. J Clin Endocrinol Metab 1996;81(8):2986-93.
2. Franklyn JA. The management of hyperthyroidism. N Engl J Med 1994;330(24):1731-8.
3. Weetman AP. Graves' disease. N Engl J Med 2000;343(17): 1236-48.
4. AACE Thyroid Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002;8(6):457-69.
5. Ginsberg J. Diagnosis and management of Graves' disease. Can Med Assoc J 2003;168(5):575-85.
6. Gittoes NJ, Franklyn JA. Hyperthyroidism: current treatment guidelines. Drugs 1998;55(4):543-53.
7. Streetman DD, Khanderia U. Diagnosis and treatment of Graves' disease. Ann Pharmacother 2003;37(7-8):1100-9.
8. Woeber KA. Update on the management of hyperthyroidism and hypothyroidism. Arch Intern Med 2000;160(8):1067-71.
9. Cooper DS. Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab 2003;88(8): 3474-81.
10. Cooper DS. Hyperthyroidism. Lancet 2003;362(9382):459-68.
11. Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism: the thyroid study group. N Engl J Med 1992; 326(26):1733-8.
12. Wiersinga WM. Preventing Graves' ophthalmopathy. N Engl J Med 1998;338(2):121-2.
13. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000;21(2):168-99.
14. 131I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002;87(3):1073-7.
15. Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 1998;83(2): 685-7.
16. Hancock LD, Tuttle RM, LeMar H, Bauman J, Patience T. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease. Clin Endocrinol (Oxf) 1997;47(4): 425-30.
17. Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism: prognostic factors for outcome. J Clin Endocrinol Metab 2001;86(8): 3611-17.
18. Leslie WD, Peterdy AE, Dupont JO. Radioiodine treatment outcomes in thyroid glands previously irradiated for Graves' hyperthyroidism. J Nucl Med 1998;39(4):712-16.
19. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab 2003; 88(3):978-83.
20. Bitton R, Sachmechi I, Benegalrao Y, Schneider BS. Leukemia after a small dose of radioiodine for metastatic thyroid cancer. J Clin Endocrinol Metab 1993;77(5):1423-6.
21. Roldan Schilling V, Fernandez Abellan P, Dominguez Escribano JR, Rivas Gonzalez C, Mut Barbera E, Calatayud Cendra R. Acute leukemias after treatment with radioiodine for thyroid cancer. Haematologica 1998;83(8):767-8.
22. Laurenti L, Salutari P, Sica S, et al. Acute myeloid leukemia after iodine-131 treatment for thyroid disorders. Ann Hematol 1998;76(6):271-2.
23. Richards EM, Marcus RE. Acute promyelocytic leukaemia following radioiodine therapy. Clin Lab Haematol 1993; 15(1):55-8.
24. Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 1999;353(9170):2111-15.
25. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American intergroup protocol. Blood 2002;100(13):4298-302.
26. Lee KH, Kim DH, Lee JS, et al. Acute promyelocytic leukemia is a distinct subset of acute myelocytic leukemia with unique clinicopathologic characteristics including longer duration of relapse free survival: experience in 13 cases. J Korean Med Sci 1994;9(6):437-43.
27. Fenaux P, Degos L. Differentiation therapy for acute promyelocytic leukemia. N Engl J Med 1997;337(15):1076-7.
28. Warrell RP Jr, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993;329(3):177-89.
29. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45.
30. Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003;21(11):2123-37.
31. Pulsoni A, Pagano L, Lo Coco F, et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood 2002;100(6):1972-6.